Evidence item

The 68-person cohort comprised predominantly white men who began ART during primary or early-stage HIV infection. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25318

Source: Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial · locator {} · excerpt hash sha256:f711c69fa224561aa020790721ad4384288e0f3dcfeea2279a329d530d6814ab

Exact excerpt

Sixty-eight adult men living with human immunodeficiency virus (HIV), who were predominantly white and initiated antiretroviral therapy (ART) during primary or early-stage infection, underwent treatment interruption and were randomly assigned to a group receiving one or two doses of two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS (arm A, n = 34) or saline (arm B, n = 34).

Linked claims

Claim	Direction	Relevance	Steps	Counted
1304f296	QUALIFY	DIRECT	0	yes

Audits

None.